Standout Papers

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer ... 2017 2026 2020 2023 1.1k
  1. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy (2017)
    George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology
  2. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 (2019)
    George W. Sledge, Masakazu Toi et al. JAMA Oncology

Immediate Impact

2 from Science/Nature 74 standout
Sub-graph 1 of 17

Citing Papers

Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
2025 Standout
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2024 Standout

Works of Olga Burdaeva being referenced

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer
2019
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
2017 Standout

Author Peers

Author Last Decade Papers Cites
Olga Burdaeva 1563 1630 73 621 27 2.0k
Yuan Liu 1141 1308 41 746 41 1.7k
Han Koh 2178 1883 28 836 25 2.7k
Meena Okera 1488 1678 21 617 32 2.0k
C. Giorgetti 2077 2144 42 874 33 2.9k
S. Phan 1604 1340 76 513 43 2.4k
Nawel Bourayou 1797 2026 23 723 23 2.3k
Yuqiu Jiang 1542 1357 122 829 26 2.3k
Kathy Puyana Theall 1828 2049 19 787 26 2.3k
Dylan Conklin 1185 1064 43 394 31 1.8k
Eric Gauthier 2337 2492 25 889 41 3.0k

All Works

Loading papers...

Rankless by CCL
2026